KG 2019
Alternative Names: JN-2019; KG-2019Latest Information Update: 28 Sep 2024
At a glance
- Originator JN Nova Pharma
- Class Antivirals; Recombinant fusion proteins
- Mechanism of Action Angiotensin-converting enzyme 2 expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Canada (Parenteral)
- 14 Aug 2020 JN Nova Pharma and National Research Council of Canada agree to co-promote KG 2019 in Canada for COVID-19 infection
- 14 Aug 2020 Preclinical trials in COVID-2019 infections in Canada (Parenteral)